MedTrace Logo

Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

NCT00957476 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-05-03

No results posted yet for this study

Summary

Randomized, double-blind placebo controlled trial of fish oil to decrease inflammation in pregnancy.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fish Oil

800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • MetroHealth Medical Center

    lead OTHER

Principal Investigators

  • Patrick M Catalano, MD · MetroHealth Medical Center

  • Sylvie Hauguel-de Mouzon, PhD · MetroHealth Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-03-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00957476 on ClinicalTrials.gov